Tesamorelin Therapy for Metabolic & Body-Composition Support

Prescription peptide therapy clinically shown to support healthy IGF-1 levels and reduce visceral abdominal fat — under medical supervision.

Prescription-only • Physician reviewed • U.S. pharmacy dispensed

Tesamorelin Therapy for Visceral Fat & Lean Muscle Support
No obligation • Online assessment • Not a weight-loss drug

What Is Tesamorelin?

Tesamorelin is a prescription peptide that works by stimulating the body’s natural growth hormone pathway. In clinical studies, it has been shown to increase IGF-1 levels and reduce visceral adipose tissue in certain adult populations, while helping support lean body mass.

Use is determined by a licensed healthcare provider based on medical eligibility.

How Tesamorelin Is Studied to Support Health

Visceral Fat Support

Studied for its role in reducing deep abdominal fat associated with metabolic risk.

Lean Mass Support

Evaluated for helping preserve lean body mass during lifestyle changes.

IGF-1 Activity

Shown in studies to support healthy IGF-1 levels.

Metabolic Balance

May support overall metabolic health under medical supervision.

Understanding Different GH-Related Therapies

Growth-hormone–related therapies differ in how they work and how they’re regulated. This comparison is for educational purposes only.

Tesamorelin Vs Sermorelin & HGH Injections

Why Choose Tesamorelin? Natural growth hormone (GH) levels decline about 1-2% per year after age 30.

Tesamorelin is a clinically validated peptide shown in studies to increase IGF-1 levels and reduce visceral adipose tissue (VAT) in adults with excess abdominal fat.

It’s been evaluated for its ability to support lean body mass and metabolic balance — under medical supervision. Tesamorelin is our Strongest Growth Hormone Stimulating Peptide

Tesamorelin Benefits:

Feature Tesamorelin Sermorelin HGH Injections
How it Works Stimulates GH + IGF-1 for metabolic support Solid GH support Direct hormone
Safety Clinically proven Safe High risk
Efficacy Fat loss + muscle retention Fat Loss & Muscle Water retention
Regulation Rx, U.S. Licensed Pharmacy Rx only Controlled
Cost Moderate, high ROI Moderate Very expensive
Best For Body recomposition support GH support Short-term bulk

Treatment selection is determined by a licensed provider.

How Body Forward Works

Get Started in a Few Simple Steps

Step 1

Online Medical Intake

Complete a secure questionnaire about your health history, lifestyle, and goals—entirely online and on your schedule.

Step 2

Telehealth Provider Consultation

Consult with one of our licensed U.S. healthcare providers online. Your provider will review your intake, answer questions, and determine whether treatment options may be appropriate.

Care from home—without in-person appointments or waiting rooms

Step 3

Personalized Care Plan & Prescription

If approved, your provider creates a personalized care plan. Your prescription is processed, and medication is discreetly shipped directly to your door.

Treatment Overview

Tesamorelin is provided as a prescription injectable peptide. Usage instructions, dosing, and duration are determined by your prescribing provider.

Frequently Asked Questions

A: No. Tesamorelin is not approved as a weight-loss medication. It is a prescription-only peptide that naturally stimulates your body’s own growth hormone (GH) release. It works by activating the pituitary gland to boost GH and increase IGF-1, which helps reduce visceral belly fat, preserve lean muscle, and improve metabolic health. Tesamorelin supports body recomposition from the inside out — promoting a leaner, stronger, more energized physique.

A: Most patients begin noticing improvements in energy, sleep, and recovery within the first 2–4 weeks.

Visible changes in body composition — including waist reduction and fat loss — typically appear around 8–12 weeks with consistent use and a balanced routine. Clinical studies confirm measurable reductions in visceral fat over this period.

Results are not guaranteed and depend on individual factors, adherence, and medical guidance.

A: Yes. Tesamorelin is a clinically validated peptide with extensive research involving thousands of patients.

When prescribed and monitored by a licensed provider, it is generally safe and well tolerated.

Some individuals may experience mild, temporary effects such as injection-site redness, tingling, or minor fluid retention. Body Forward’s providers review your medical history and track your progress to ensure safe, appropriate use.

A: Tesamorelin is a once-daily subcutaneous injection (just under the skin), typically taken in the evening before bed.

It’s injected directly into the stomach area (abdomen) using a small insulin-style needle.

The process is quick, nearly painless, and easy to self-administer. Body Forward provides step-by-step instructions and clinical support, ensuring a smooth experience from your first dose onward.

Medication is shipped pre-mixed from a licensed pharmacy and arrives cold-packed, with no mixing required. Always follow your pharmacy’s instructions.

A: No. Tesamorelin should not be combined with other GH-releasing peptides such as Sermorelin or CJC-1295.

These compounds act on similar receptors, and stacking them can interfere with your body’s natural hormone rhythm and increase side effect risks without added benefit.

Tesamorelin is designed to work as a standalone, clinically proven peptide — delivering the strongest, most targeted GH response available through Body Forward.

Clinically Guided Peptide Therapy — Without the Guesswork

Complete a free online assessment to see if Tesamorelin may be appropriate for you.

No guarantees • Results vary • Prescription required
This site is for informational purposes only and does not provide medical advice. Tesamorelin is a prescription medication available only after evaluation by a licensed healthcare provider. Individual results vary. Not approved for weight loss.

Supporting Studies

Chapman IM et al. JCEM. 2005; 90(12): 6791–6800. – Dose-dependent IGF-1 increase (~48–65%) in healthy adults. PubMed

FDA Clinical Pharmacology Review – Tesamorelin (Egrifta®). 2010. AccessData.FDA.gov

Falutz J et al. N Engl J Med. 2007; 357(23): 2359–70. – Reduced visceral fat, increased IGF-1 in HIV-associated lipodystrophy. PubMed

Stanley TL et al. JAMA. 2014; 312(4): 380–389. – Visceral and liver fat reduction with Tesamorelin. JAMA Network

Falutz J et al. JCEM. 2010; 95(9): 4291–4304.-Phase 3 pooled analysis confirming efficacy and safety. Oxford Academic